FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2141830999> ?p ?o ?g. }

• W2141830999 endingPage "567" @default.
• W2141830999 startingPage "555" @default.
• W2141830999 abstract "Abstract Purpose: To compare the efficacy and tolerability of the mitogen-activated protein (MAP)/extracellular signal-regulated (ERK) kinase (MEK) 1/2 inhibitor selumetinib versus temozolomide in chemotherapy-naive patients with unresectable stage III/IV melanoma. Experimental Design: This phase II, open-label, multicenter, randomized, parallel-group study examined the effect of 100 mg oral selumetinib twice daily in 28-day cycles versus oral temozolomide (200 mg/m2/d for 5 days, then 23 days off-treatment). The primary endpoint was progression-free survival. Results: Two hundred patients were randomized. Progression-free survival did not differ significantly between selumetinib and temozolomide (median time to event 78 and 80 days, respectively; hazard ratio, 1.07; 80% confidence interval, 0.86–1.32). Objective response was observed in six (5.8%) patients receiving selumetinib and nine (9.4%) patients in the temozolomide group. Among patients with BRAF mutations, objective responses were similar between selumetinib and temozolomide groups (11.1% and 10.7%, respectively). However, five of the six selumetinib partial responders were BRAF mutated. Frequently reported adverse events with selumetinib were dermatitis acneiform (papular pustular rash; 59.6%), diarrhea (56.6%), nausea (50.5%), and peripheral edema (40.4%), whereas nausea (64.2%), constipation (47.4%), and vomiting (44.2%) were reported with temozolomide. Conclusions: No significant difference in progression-free survival was observed between patients with unresectable stage III/IV melanoma unselected for BRAF/NRAS mutations, who received therapy with selumetinib or temozolomide. Five of six patients with partial response to selumetinib had BRAF mutant tumors. Clin Cancer Res; 18(2); 555–67. ©2011 AACR." @default.
• W2141830999 created "2016-06-24" @default.
• W2141830999 creator A5007239425 @default.
• W2141830999 creator A5051430596 @default.
• W2141830999 creator A5055038393 @default.
• W2141830999 creator A5056132643 @default.
• W2141830999 creator A5057277696 @default.
• W2141830999 creator A5064543105 @default.
• W2141830999 creator A5070927117 @default.
• W2141830999 creator A5072123060 @default.
• W2141830999 creator A5075566772 @default.
• W2141830999 creator A5076054848 @default.
• W2141830999 creator A5089297467 @default.
• W2141830999 date "2012-01-15" @default.
• W2141830999 modified "2023-09-30" @default.
• W2141830999 title "Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma" @default.
• W2141830999 cites W1516437155 @default.
• W2141830999 cites W1752845679 @default.
• W2141830999 cites W1773110831 @default.
• W2141830999 cites W1917632054 @default.
• W2141830999 cites W1925900276 @default.
• W2141830999 cites W1935448348 @default.
• W2141830999 cites W1965414206 @default.
• W2141830999 cites W1979775163 @default.
• W2141830999 cites W2005141789 @default.
• W2141830999 cites W2039564643 @default.
• W2141830999 cites W2070871778 @default.
• W2141830999 cites W2085763302 @default.
• W2141830999 cites W2088293068 @default.
• W2141830999 cites W2104788624 @default.
• W2141830999 cites W2106543129 @default.
• W2141830999 cites W2108517627 @default.
• W2141830999 cites W2115218873 @default.
• W2141830999 cites W2123541095 @default.
• W2141830999 cites W2124301770 @default.
• W2141830999 cites W2124662474 @default.
• W2141830999 cites W2128445526 @default.
• W2141830999 cites W2128542677 @default.
• W2141830999 cites W2129400742 @default.
• W2141830999 cites W2135925159 @default.
• W2141830999 cites W2140633731 @default.
• W2141830999 cites W2147017515 @default.
• W2141830999 cites W2149721689 @default.
• W2141830999 cites W2151067943 @default.
• W2141830999 cites W2153216846 @default.
• W2141830999 cites W2155777530 @default.
• W2141830999 cites W2157016650 @default.
• W2141830999 cites W2161204067 @default.
• W2141830999 cites W2161630562 @default.
• W2141830999 cites W2162147795 @default.
• W2141830999 cites W2163592822 @default.
• W2141830999 cites W2245828370 @default.
• W2141830999 cites W2257566384 @default.
• W2141830999 cites W2337607062 @default.
• W2141830999 doi "https://doi.org/10.1158/1078-0432.ccr-11-1491" @default.
• W2141830999 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3549298" @default.
• W2141830999 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22048237" @default.
• W2141830999 hasPublicationYear "2012" @default.
• W2141830999 type Work @default.
• W2141830999 sameAs 2141830999 @default.
• W2141830999 citedByCount "244" @default.
• W2141830999 countsByYear W21418309992012 @default.
• W2141830999 countsByYear W21418309992013 @default.
• W2141830999 countsByYear W21418309992014 @default.
• W2141830999 countsByYear W21418309992015 @default.
• W2141830999 countsByYear W21418309992016 @default.
• W2141830999 countsByYear W21418309992017 @default.
• W2141830999 countsByYear W21418309992018 @default.
• W2141830999 countsByYear W21418309992019 @default.
• W2141830999 countsByYear W21418309992020 @default.
• W2141830999 countsByYear W21418309992021 @default.
• W2141830999 countsByYear W21418309992022 @default.
• W2141830999 countsByYear W21418309992023 @default.
• W2141830999 crossrefType "journal-article" @default.
• W2141830999 hasAuthorship W2141830999A5007239425 @default.
• W2141830999 hasAuthorship W2141830999A5051430596 @default.
• W2141830999 hasAuthorship W2141830999A5055038393 @default.
• W2141830999 hasAuthorship W2141830999A5056132643 @default.
• W2141830999 hasAuthorship W2141830999A5057277696 @default.
• W2141830999 hasAuthorship W2141830999A5064543105 @default.
• W2141830999 hasAuthorship W2141830999A5070927117 @default.
• W2141830999 hasAuthorship W2141830999A5072123060 @default.
• W2141830999 hasAuthorship W2141830999A5075566772 @default.
• W2141830999 hasAuthorship W2141830999A5076054848 @default.
• W2141830999 hasAuthorship W2141830999A5089297467 @default.
• W2141830999 hasBestOaLocation W21418309991 @default.
• W2141830999 hasConcept C121608353 @default.
• W2141830999 hasConcept C126322002 @default.
• W2141830999 hasConcept C143998085 @default.
• W2141830999 hasConcept C168563851 @default.
• W2141830999 hasConcept C184235292 @default.
• W2141830999 hasConcept C197934379 @default.
• W2141830999 hasConcept C207103383 @default.
• W2141830999 hasConcept C2776087337 @default.
• W2141830999 hasConcept C2776694085 @default.
• W2141830999 hasConcept C2777389519 @default.
• W2141830999 hasConcept C2777482430 @default.
• W2141830999 hasConcept C2777658100 @default.

• next